Vigabatrin in childhood epilepsy

O. Dulac, C. Chiron, D. Luna, R. Cusmai, N. Pajot, D. Beaumont, S. Mondragon

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period. All the children were receiving one to three other antiepileptic drugs, the doses of which were not changed during the 6-month dose titration phase. Following the introduction of vigabatrin, 11 patients became seizure free, and 28 responded with a greater than 50% reduction in seizure frequency. The following types of epilepsy responded favorably in order of decreasing efficacy: cryptogenic and symptomatic partial epilepsy, other symptomatic generalized epilepsy, and Lennox-Gastaut syndrome. However, three of nine patients with myoclonic epilepsy showed an increase in seizure frequency. Optimal responses were found with vigabatrin doses of 40 to 80 mg/kg/day, although no significant adverse effects were noted with doses of higher than 100 mg/kg/day. Thirty-eight responders continued on vigabatrin, 19 of whom have been treated for more than 1 year, with generally good efficacy. As a result of discontinuing concomitant antiepileptics, six patients are on monotherapy with vigabatrin, four of whom are seizure free. Vigabatrin tolerability was good, with 39 of 66 children reporting no adverse effects. Hyperkinesia was reported in 17 patients (26%), and two had to drop out of the study. All these patients had a history of hyperkinesia or mental retardation. In patients in whom vigabatrin dose was reduced because of hyperkinesia, a dose increase could later be instituted without recurrence of symptoms. There was no change in neurologic examination and no drug-related abnormalities in clinical laboratory data. It is concluded that this study shows that vigabatrin is safe and effective in the treatment of refractory epilepsy of various types in children. The recommended starting dose is 40 mg/kg/day, which can be increased up to 80 mg/kg/day, depending on clinical response.

Original languageEnglish
JournalJournal of Child Neurology
Volume6
Issue numberSUPPL. 2
Publication statusPublished - 1991

Fingerprint

Vigabatrin
Epilepsy
Hyperkinesis
Seizures
Anticonvulsants
Myoclonic Epilepsy
Generalized Epilepsy
Partial Epilepsy
Neurologic Examination
Intellectual Disability
Placebos
Recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Dulac, O., Chiron, C., Luna, D., Cusmai, R., Pajot, N., Beaumont, D., & Mondragon, S. (1991). Vigabatrin in childhood epilepsy. Journal of Child Neurology, 6(SUPPL. 2).

Vigabatrin in childhood epilepsy. / Dulac, O.; Chiron, C.; Luna, D.; Cusmai, R.; Pajot, N.; Beaumont, D.; Mondragon, S.

In: Journal of Child Neurology, Vol. 6, No. SUPPL. 2, 1991.

Research output: Contribution to journalArticle

Dulac, O, Chiron, C, Luna, D, Cusmai, R, Pajot, N, Beaumont, D & Mondragon, S 1991, 'Vigabatrin in childhood epilepsy', Journal of Child Neurology, vol. 6, no. SUPPL. 2.
Dulac O, Chiron C, Luna D, Cusmai R, Pajot N, Beaumont D et al. Vigabatrin in childhood epilepsy. Journal of Child Neurology. 1991;6(SUPPL. 2).
Dulac, O. ; Chiron, C. ; Luna, D. ; Cusmai, R. ; Pajot, N. ; Beaumont, D. ; Mondragon, S. / Vigabatrin in childhood epilepsy. In: Journal of Child Neurology. 1991 ; Vol. 6, No. SUPPL. 2.
@article{21da834c6c2c4dd09f01e0267f5f03a4,
title = "Vigabatrin in childhood epilepsy",
abstract = "Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period. All the children were receiving one to three other antiepileptic drugs, the doses of which were not changed during the 6-month dose titration phase. Following the introduction of vigabatrin, 11 patients became seizure free, and 28 responded with a greater than 50{\%} reduction in seizure frequency. The following types of epilepsy responded favorably in order of decreasing efficacy: cryptogenic and symptomatic partial epilepsy, other symptomatic generalized epilepsy, and Lennox-Gastaut syndrome. However, three of nine patients with myoclonic epilepsy showed an increase in seizure frequency. Optimal responses were found with vigabatrin doses of 40 to 80 mg/kg/day, although no significant adverse effects were noted with doses of higher than 100 mg/kg/day. Thirty-eight responders continued on vigabatrin, 19 of whom have been treated for more than 1 year, with generally good efficacy. As a result of discontinuing concomitant antiepileptics, six patients are on monotherapy with vigabatrin, four of whom are seizure free. Vigabatrin tolerability was good, with 39 of 66 children reporting no adverse effects. Hyperkinesia was reported in 17 patients (26{\%}), and two had to drop out of the study. All these patients had a history of hyperkinesia or mental retardation. In patients in whom vigabatrin dose was reduced because of hyperkinesia, a dose increase could later be instituted without recurrence of symptoms. There was no change in neurologic examination and no drug-related abnormalities in clinical laboratory data. It is concluded that this study shows that vigabatrin is safe and effective in the treatment of refractory epilepsy of various types in children. The recommended starting dose is 40 mg/kg/day, which can be increased up to 80 mg/kg/day, depending on clinical response.",
author = "O. Dulac and C. Chiron and D. Luna and R. Cusmai and N. Pajot and D. Beaumont and S. Mondragon",
year = "1991",
language = "English",
volume = "6",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Vigabatrin in childhood epilepsy

AU - Dulac, O.

AU - Chiron, C.

AU - Luna, D.

AU - Cusmai, R.

AU - Pajot, N.

AU - Beaumont, D.

AU - Mondragon, S.

PY - 1991

Y1 - 1991

N2 - Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period. All the children were receiving one to three other antiepileptic drugs, the doses of which were not changed during the 6-month dose titration phase. Following the introduction of vigabatrin, 11 patients became seizure free, and 28 responded with a greater than 50% reduction in seizure frequency. The following types of epilepsy responded favorably in order of decreasing efficacy: cryptogenic and symptomatic partial epilepsy, other symptomatic generalized epilepsy, and Lennox-Gastaut syndrome. However, three of nine patients with myoclonic epilepsy showed an increase in seizure frequency. Optimal responses were found with vigabatrin doses of 40 to 80 mg/kg/day, although no significant adverse effects were noted with doses of higher than 100 mg/kg/day. Thirty-eight responders continued on vigabatrin, 19 of whom have been treated for more than 1 year, with generally good efficacy. As a result of discontinuing concomitant antiepileptics, six patients are on monotherapy with vigabatrin, four of whom are seizure free. Vigabatrin tolerability was good, with 39 of 66 children reporting no adverse effects. Hyperkinesia was reported in 17 patients (26%), and two had to drop out of the study. All these patients had a history of hyperkinesia or mental retardation. In patients in whom vigabatrin dose was reduced because of hyperkinesia, a dose increase could later be instituted without recurrence of symptoms. There was no change in neurologic examination and no drug-related abnormalities in clinical laboratory data. It is concluded that this study shows that vigabatrin is safe and effective in the treatment of refractory epilepsy of various types in children. The recommended starting dose is 40 mg/kg/day, which can be increased up to 80 mg/kg/day, depending on clinical response.

AB - Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period. All the children were receiving one to three other antiepileptic drugs, the doses of which were not changed during the 6-month dose titration phase. Following the introduction of vigabatrin, 11 patients became seizure free, and 28 responded with a greater than 50% reduction in seizure frequency. The following types of epilepsy responded favorably in order of decreasing efficacy: cryptogenic and symptomatic partial epilepsy, other symptomatic generalized epilepsy, and Lennox-Gastaut syndrome. However, three of nine patients with myoclonic epilepsy showed an increase in seizure frequency. Optimal responses were found with vigabatrin doses of 40 to 80 mg/kg/day, although no significant adverse effects were noted with doses of higher than 100 mg/kg/day. Thirty-eight responders continued on vigabatrin, 19 of whom have been treated for more than 1 year, with generally good efficacy. As a result of discontinuing concomitant antiepileptics, six patients are on monotherapy with vigabatrin, four of whom are seizure free. Vigabatrin tolerability was good, with 39 of 66 children reporting no adverse effects. Hyperkinesia was reported in 17 patients (26%), and two had to drop out of the study. All these patients had a history of hyperkinesia or mental retardation. In patients in whom vigabatrin dose was reduced because of hyperkinesia, a dose increase could later be instituted without recurrence of symptoms. There was no change in neurologic examination and no drug-related abnormalities in clinical laboratory data. It is concluded that this study shows that vigabatrin is safe and effective in the treatment of refractory epilepsy of various types in children. The recommended starting dose is 40 mg/kg/day, which can be increased up to 80 mg/kg/day, depending on clinical response.

UR - http://www.scopus.com/inward/record.url?scp=0026050667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026050667&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - SUPPL. 2

ER -